Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

FT

First Tracks Biotherapeutics, Inc.

$46.13

-0.76 (-1.63%)

Market Cap
1.61 B
EPS
-
P/E Ratio
-
Value Trade
33.75 M
SEC Financials
Q2 2026

  • Dilution Risk

    25%

  • R&D Expenses

    25.64 M

  • Total Assets

    183.14 M

  • Total Liabilities

    183.14 M

  • Equity

    168.80 M

1.81 %
Week
34.22 %
1 Month
154.02 %
3 Month
148.01 %
6 Month
-14.1 %
5 Year
-14.1 %
All Time
Cash Data
Stable

  • Cash Position

    168.02 M

  • Monthly Burn

    11.65 M

  • Runway

    14.4 mo

  • Burn Trend

    Stable

  • SEC Filing

    Aug 12, 2026
Overview
Volume
456.93 K
52 Week Range
14.79 - 26.80
% held by Insiders
-
% held by Institutions
-
Enterprise Value
1.44 B
Total Shares
34.89 M
Short %
12.13 %
Float Shares
32.62 M
Company Description
HQ: 10770 WATERIDGE CIRCLE, SAN DI...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
Unlock Historical Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TRAX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
TRAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TRAX
Aug 12, 2026
TRAXPhases
▼ -1.6%today

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics announced its financial results for Q2 2026, highlighting the completion of enrollment for Cohort 1 of the Phase 1b trial of ANB033 in celiac disease. The FDA granted Fast Track designation for ANB033, with top-line data from Cohort 1 expected in Q4 2026. The company is also enrolling patients for a trial in eosinophilic esophagitis and plans to expand ANB033 into additional indications in 2027.

Read more →
-TRAX
May 22, 2026
TRAXConferences/Events

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - May 21, 2026

First Tracks Biotherapeutics, a clinical-stage biotech firm, announced its participation in several upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. CEO Daniel Faga and other executives will represent the company. A live webcast of the presentations will be available, with replays accessible for 30 days.

Read more →
-TRAX
May 21, 2026
TRAXConferences/Events

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics, a clinical-stage biotechnology firm, announced its participation in several upcoming investor conferences. CEO Daniel Faga and other executives will present at the 2026 Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. The company focuses on developing antibody therapies for autoimmune and inflammatory diseases.

Read more →
-TRAX
May 14, 2026
TRAXPhases

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update • First Tracks launched April 20 th with a two-year cash-runway to advance ANB033 through celiac disease and

First Tracks Biotherapeutics, Inc., reported its financial results for the first quarter of 2026, highlighting a significant launch with $180 million in cash. The company aims to advance its lead candidate ANB033 through ongoing Phase 1b trials in celiac disease and eosinophilic esophagitis. It also received positive feedback from the FDA regarding the development pathway for rosnilimab in rheumatoid arthritis. However, the company recorded a net loss of $50.5 million, reflecting increased general administrative costs associated with its recent separation from AnaptysBio.

Read more →
-TRAX
Apr 20, 2026
TRAXGeneral

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today

First Tracks Biotherapeutics has officially debuted on Nasdaq under the ticker symbol TRAX, launching as a clinical-stage biotech company focused on developing antibody therapeutics for autoimmune diseases. The company has announced a robust cash reserve of $180 million, which supports its initial programs, including ANB033 for celiac disease. Trading begins today, marking the company's emergence after distribution to AnaptysBio shareholders. First Tracks aims to make meaningful advancements in managing immune pathway-related diseases.

Read more →
-TRAX
Mar 26, 2026
TRAXGeneral

Dear Anaptys and future First Tracks Bio shareholders, In September 2025, we announced our intention to separate our biopharma operations from our substantial royalty assets to unlock value by creating two publicly trade

AnaptysBio, Inc. has announced plans to separate its biopharma operations from its royalty assets, creating two publicly traded companies. The newly formed First Tracks Biotherapeutics, Inc. (TRAX) will handle the biopharma segment and is set to distribute shares to Anaptys shareholders in a tax-free spin-off. The distribution is scheduled for April 20, 2026, and existing shareholders will receive shares on a one-for-one basis for each share of Anaptys they hold. The spin-off aims to provide a focused operational strategy and is anticipated to attract investor interest.

Read more →
Competitive Position
How TRAX ranks across every disease it competes in
Competitive Position is a premium feature
See how TRAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial